期刊文献+

慢加急性肝衰竭患者血小板计数及其动态变化的临床意义 被引量:9

Clinical significance of platelet count and its dynamic change in patients with acute-on-chronic liver failure
下载PDF
导出
摘要 目的肝衰竭患者往往存在严重的血小板减少现象。对慢加急性肝衰竭(ACLF)患者血小板的动态变化进行监测分析,探讨血小板水平及其变化与患者预后的关系,并分析血小板减少的原因。方法收集2014年9月-2016年9月于首都医科大学附属北京佑安医院住院的54例ACLF患者的临床资料。血小板由全自动血常规分析仪检测获得,促血小板生成素(TPO)水平采用ELISA方法检测获得。正态分布的计量资料2组间比较采用t检验;非正态分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料组间比较采用χ2检验。预后相关参数采用单因素及多因素logistic回归分析;应用受试者工作特征曲线(ROC曲线)分析血小板计数变化对肝衰竭的诊断价值。结果 ACLF患者出院时死亡18例,病死率为33.3%。ACLF患者基线血小板为80.0(36.0~334.0)×109/L,较正常值明显下降。出院前血小板下降幅度在死亡组显著大于存活组[(-43.4±58.9)×109/L vs(-11.5±29.1)×109/L,t=-2.827,P=0.041]。以血小板变化-27.5×109/L为cut-off值,血小板变化>-27.5×109/L和≤-27.5×109/L组病死率比较,差异有统计学意义(22.2%vs 72.2%,χ2=12.623,P<0.01)。单因素分析表明:血小板变化、PTA、Glu为患者预后的影响因素。多因素分析表明血小板变化为ACLF患者预后的独立影响因素,ROC曲线下面积为0.743。其中24例ACLF患者检测了血浆TPO水平,出院时死亡8例,病死率为33.3%。ACLF存活组与死亡组TPO水平分别为(91.8±39.8)pg/ml和(93.3±46.5)pg/ml,2组比较差异无统计学意义(t=0,P=0.938)。结论 ACLF患者基线血小板显著低于正常血小板的范围,血小板下降幅度是ACLF患者出院时死亡的独立影响因素,血小板减少与TPO水平下降无关。 Objective To investigate the dynamic change of platelets in patients with acute-on-chronic liver failure(ACLF),the association of platelet count and its change with patients’ prognosis,and the cause of thrombocytopenia,since severe thrombocytopenia is often seen in patients with liver failure.Methods A total of 54 patients with ACLF who were hospitalized in Beijing You’ an Hospital,Capital Medical University,from September 2014 to September 2016 were enrolled,and their clinical data were collected.An automatic blood analyzer was used to measure platelet count,and ELISA was used to measure the level of thrombopoietin(TPO).The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups.The univariate and multivariate logistic regression analyses were used for prognostic parameters,and the receiver operating characteristic(ROC)curve was used to analyze the value of the change in platelet count in the diagnosis of liver failure.Results A total of 18 ACLF patients died before discharge,resulting in a mortality rate of 33.3%.These patients had a mean platelet count of 80.0 × 10^9/L [range(36.0-334.0) ×10^9/L],which was significantly lower than the normal value.The death group had a significantly greater reduction in platelet count than the survival group [(-43.4 ± 58.9) × 10^9/L vs(-11.5 ± 29.1) × 10^9/L,t =-2.827,P = 0.041].With -27.5 × 10^9/L as the cut-off value of the change in platelet count,there was a significant difference in mortality rate between the platelet count change 〉-27.5 × 10^9/L group and the platelet count change ≤-27.5 × 109/L group(22.2% vs 72.2%,χ^2= 12.623,P 〈 0.01).The univariate analysis showed that platelet change,prothrombin time activity,and fasting blood glucose were influencing factors for patients’ prognosis,and the multivariate analysis showed that platelet change was an independent influencing factor for the prognosis of ACLF patients,with an area under the ROC curve of0.743.The plasma level of TPO was measured for 24 patients,among whom 8 died before discharge,resulting in a mortality rate of 33.3%.There was no significant difference in the level of TPO between the survival group and the death group(91.8 ± 39.8 pg/ml vs 93.3 ± 46.5 pg/ml,t = 0,P = 0.938).Conclusion Baseline platelet count in ACLF patients is significantly lower than the normal value.The reduction in platelet count is an independent risk factor for death before discharge in ACLF patients.Thrombocytopenia may not be associated with the reduction in TPO.
作者 许姗姗 韦新焕 林伟 张晶 XU Shanshan;WEI Xinhuan;LIN Wei;et al(Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China)
出处 《临床肝胆病杂志》 CAS 北大核心 2018年第4期810-813,共4页 Journal of Clinical Hepatology
基金 艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2017ZX10105005-003-003 2017ZX10203201-005)
关键词 肝功能衰竭 血小板减少 血小板生成素 预后 liver failure thrombocytopenia thrombopoietin prognosis
  • 相关文献

参考文献3

二级参考文献34

  • 1Tao Han,Ying Liu,Huan Liu,Zheng-Yan Zhu,Yan Li,Shi-Xiang Xiao,Zhen Guo,Zhen-Gang Zhao,Department of Hepatology,Tianjin Institute of Hepatobiliary Disease,Tianjin Key Laboratory of Artificial Cells,Tianjin Third Central Hospital,Tianjin Medical University,83 Jintang Road,Tianjin 300170, China.Serum thymosin β4 levels in patients with hepatitis B virus-related liver failure[J].World Journal of Gastroenterology,2010,16(5):625-630. 被引量:20
  • 2中国肝性脑病诊治共识意见(2013年,重庆)[J].中国医学前沿杂志(电子版),2014,6(2):81-93. 被引量:81
  • 3Xue-Zhang Duan,Fang-Fang Liu,Jing-Jing Tong,Hao-Zhen Yang,Jing Chen,Xiao-Yan Liu,Yuan-Li Mao,Shao-Jie Xin,Jin-Hua Hu.Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acuteon-chronic liver failure[J].World Journal of Gastroenterology,2013,19(7):1104-1110. 被引量:36
  • 4Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量:829
  • 5Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure : consensus recommendations of the Asian Pacific Associationliver (APASL). Hepatol Int, 2009, 3; 269- 282.
  • 6Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol, 2008, 48: 1000- 1007.
  • 7Pradella P, Bonetto S, Turchetto S, et al. Platelet production and destruction in liver cirrhosis. J Hepatol, 2011, 54:894 -900.
  • 8Moiler HJ. Soluble CD163. Scand J Clin Lab Invest, 2012, 72: 1- 13.
  • 9Aster RH. Pooling o3 platelets in the spleen: role in the pathogenesis of " hypersplenic" thrombocytopenia. J Clin Invest, 1966, 45:645-657.
  • 10Ten Cate H. Trombocytopenia: one of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb, 2003, 33:413-416.

共引文献38

同被引文献72

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部